Hearing Impairment in Long-Term Type 1 Diabetes

长期 1 型糖尿病导致的听力障碍

• 批准号: 8642988
• 负责人: Rose A Gubitosi-Klug
• 金额: $ 235.76万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8642988
• 关键词: Air; Alcohols; Antihypertensive Agents; Auditory; Behavioral; Biochemical; Blood Pressure; Cardiac; Cardiovascular Diseases; Characteristics; Clinic; Clinical; Complications of Diabetes Mellitus; Control Groups; Coronary; Data; Diabetes Mellitus; Dose; Epidemiology; Equipment and supply inventories; Ethnic Origin; Exercise; Exposure to; Family history of; Frequencies; Guidelines; Health Benefit; Hearing; Height; Hyperglycemia; Hypoglycemia; Income; Individual; Insulin; Insulin-Dependent Diabetes Mellitus; Intervention; Kidney Diseases; Lead; Lipids; Magnetic Resonance Imaging; Marital Status; Measurement; Measures; Medical History; Mental Depression; Metabolic; Mission; Noise; Non-Steroidal Anti-Inflammatory Agents; Obesity; Occupations; Peripheral; Persons; Pharmaceutical Preparations; Prevalence; Protocols documentation; Publishing; Pulse Rates; Pure-Tone Audiometry; Quality of life; Questionnaires; Recommendation; Recording of previous events; Retinal Diseases; Risk Factors; Self-Administered; Sex Education; Smoking; Testing; Ultrasonography; Update; Weight; X-Ray Computed Tomography; aging demographic; autonomic neuropathy; base; blood glucose regulation; chemotherapy; cohort; comorbidity; conventional therapy; diabetes control; drinking; follow-up; glycemic control; hearing impairment; non-diabetic; prevent; primary outcome; public health relevance; screening; urologic; volunteer

DESCRIPTION (provided by applicant): The primary mission of the DCCT/EDIC study is to determine the effects of glycemic control and of non- hyperglycemic risk factors on the complications of type 1 diabetes. Persons with type 1 diabetes may have a greater prevalence of hearing loss than comparable non-diabetic individuals. Whether hearing loss is altered by the degree of present or past glucose control or the presence of other diabetes complications is unknown. The DCCT/EDIC cohort provides an excellent opportunity to characterize hearing impairment in type 1 diabetes owing to its long term follow-up of the cohort (30 years). We propose to utilize both a hearing questionnaire and pure tone audiometry testing to define the auditory capability of the entire DCCT/EDIC cohort, to be compared with the results of like assessments in a comparable group of approximately 260 individuals without diabetes, We anticipate that at least 1,100 of the 1,350 surviving EDIC volunteers will volunteer. A hearing questionnaire will be administered by each clinic. Standardized pure tone audiometry testing will be done by each clinic. The primary outcome is the prevalence of hearing impairment based on a mean of the pure tone average of thresholds at 500, 1000, 2000, and 4000 Hz. Hearing impairment will be defined as a pure tone average greater than 25 dB. The Specific Aims of this proposal are: 1) To determine whether hearing impairment, based on both self-administered questionnaire and measurement of air conduction pure tone thresholds at various frequencies, is more prevalent in the DCCT/EDIC cohort than in a control group without diabetes; 2) To assess the association of hyperglycemia, as measured by the mean A1C over ~30 years of the DCCT/EDIC study, with the prevalence and extent of hearing impairment; 3) To determine whether the prevalence and extent of hearing impairment differs between the prior DCCT intensive treatment group versus the conventional treatment groups; and 4) To evaluate whether other determinants (e.g., demographic, clinical status, biochemical parameters, behavioral characteristics, and environmental) are related to the prevalence and extent of hearing impairment in the DCCT/EDIC cohort. The above protocol will have greater than 90% power to detect a two-fold difference in the odds of having a hearing loss between the controls and the DCCT/EDIC volunteers. The results will establish the hearing capabilities of individuals with type 1 diabetes compared to non diabetic controls, the impact of glycemic control, the presence of other diabetic complications on hearing, and the identification of hearing impairment risk factors (demographic, clinical, biochemical, behavioral, and environmental). We anticipate that these data will lead to audiological screening and testing recommendations that will have a major quality of life health benefit for all individuals with type 1 diabetes.

描述（由申请方提供）：DCCT/EDIC研究的主要使命是确定血糖控制和非高血糖风险因素对1型糖尿病并发症的影响。1型糖尿病患者听力损失的患病率可能高于非糖尿病患者。目前尚不清楚听力损失是否会因当前或过去的血糖控制程度或其他糖尿病并发症的存在而改变。DCCT/EDIC队列提供了一个很好的机会来表征1型糖尿病患者的听力损害，因为它对队列进行了长期随访（30年）。我们建议使用听力问卷和纯音测听测试来定义整个DCCT/EDIC队列的听觉能力，并与大约260名无糖尿病个体的类似评估结果进行比较。我们预计，1,350名存活的EDIC志愿者中至少有1,100名将成为志愿者。每个诊所将进行听力问卷调查。每个诊所将进行标准化纯音测听测试。主要结果是基于500、1000、2000和4000 Hz的纯音平均阈值的平均值的听力损害的患病率。听力损伤将被定义为纯音平均值大于25 dB。本研究的具体目的是：1）根据自填问卷和不同频率下的气导纯音听阈测量，确定DCCT/EDIC队列中的听力损害是否比无糖尿病的对照组更普遍; 2）评估DCCT/EDIC研究中约30年的平均A1 C测量的高血糖与听力损害的患病率和程度的关系; 3）确定先前DCCT强化治疗组与常规治疗组之间听力损伤的患病率和程度是否不同;以及4）评估其他决定因素（例如，人口统计学、临床状态、生化参数、行为特征和环境）与DCCT/EDIC队列中听力损伤的患病率和程度相关。上述方案将具有大于90%的功效来检测对照组和DCCT/EDIC志愿者之间听力损失几率的两倍差异。结果将确定1型糖尿病患者与非糖尿病对照者相比的听力能力、血糖控制的影响、其他糖尿病并发症对听力的存在以及听力损害风险因素的识别（人口统计学、临床、生化、行为和环境）。我们预计，这些数据将导致听力筛查和测试的建议，将有一个主要的生活质量的健康益处的所有个人与1型糖尿病。